The Good, the Bad and the Ugly of the NIHSS: Time for a Change?

August 31, 2021
The NIHSS remains the fundamental assessment of stroke severity. However, some have called for modifying the NIHSS to better capture disability. Is it time to change the NIHSS?
0 Comments

What Else Beyond the NIHSS Should We Be Doing Clinically?

August 24, 2021
The NIHSS was a research tool meant to limit variability and provide uniform quantifiable assessments  of stroke severity.  As the de facto standard for stroke exams and scores, it has withstood the test of time.  However, there is more to the assessment of acute stroke severity and this podcast takes a deep dive into what else we need to be doing besides the NIHSS.
0 Comments

The Clock Is Dead - The Reign of Tissue Imaging

August 17, 2021
Mismatch is your friend if you want to treat acute stroke patients beyond 3 hrs. While the clock was once the king, tissue imaging may now define what brain is salvageable and what has been lost. Listen here and see if you agree that the clock is dead in stroke.
0 Comments

Defining the SOC - Is 4.5 Hrs the Real Answer?

August 10, 2021
The standard of care can feel elusive. Listen here as Dr. Knight shares his expertise regarding the definition of the SOC in extended window therapy for tPA. It's not a simple question and Dr. Knight is the one to answer it.
0 Comments

How Do I Identify Patients at Risk for a Secondary Event Following an Initial Acute Ischemic Stroke?

August 3, 2021
Identification of patients at high risk for secondary ischemic event, after initial event or post TIA...is minimal tissue damage really that big of a deal related to secondary stroke? Drs. Galen Henderson of Brigham and Women’s Hospital and Jordan Bonomo of the University of Cincinnati discuss key perspectives from a neurocritical, emergency medicine, and stroke perspective related to this important area of medicine.
0 Comments
RSS
123578910Last
Categories
More Entries

Dec 4

IV tPA for Acute Strokes in Patients with COVID - What Does the Limited Evidence Mean?

Brian Gibler posted on 12/4/2020

 

The incidence of acute stroke in COVID-19 patients occurs at a rate that is at least 7 times greater than the general population. Controversy about the safety and efficacy of IV-tPA remains.

Dr. Matthew Smith, a fellow in neurocritical care and endovascular neurointervention presents key data and recommendations regarding the treatment of acute stroke in patients with COVID. Addressing the initial data from the early days of the pandemic and the newer data released, Dr. Smith guides the learner through an assessment of the efficacy and safety of IV-rtPA in the treatment of acute strokes in the era of COVID.

0 Comments
Tweet Share
Please login or register to post comments.
STAY CONNECTED
Let’s expand your stroke education network. Follow us on Twitter to get the latest updates about stroke education and stay up-to-date on hot topics in stroke care.
@stroke_journey
ABOUT THE STROKE JOURNEY
The Stroke Journey is an initiative developed by The National Stroke Education Center (NSEC) that strives to be the premier source of educational information for the diagnosis and treatment of stroke in the United States. NSEC extends the world-class educational expertise of the University of Cincinnati Department of Emergency Medicine and its partners via a variety of traditional and digital resources. NSEC and The Stroke Journey are dedicated to providing outstanding stroke education with timely material that mirrors the real-time changes in the medical education and stroke care landscape.
OUR PARTNERS
The Stroke Journey is a collaboration between the NSEC, EMCREG-International, and MedEd On The Go. Together we are committed to providing high-quality stroke education for healthcare professionals.
NSEC Sponsor Logo
EMREG Sponsor Logo
MedEd Sponsor Logo
Copyright 2024 The Stroke Journey | Privacy Policy | Terms of Use | Help & Support
Copyright 2024 The Stroke Journey
Privacy Policy | Terms of Use | Help & Support
Powered by MedEdOTG.com